NuVasive Full Year 2022 Net Sales Increase 5.5%

NuVasive Inc., a leader in spine technology innovation, has shared financial results for the quarter and full year ended December 31, 2022.
 
NuVasive reported fourth quarter 2022 total net sales of $305.4 million, a 1.1% increase as reported and a 4.8% increase on a constant currency basis, compared to $302.1 million in the prior year period. Fourth quarter 2022 total net sales were driven by further adoption of new products and solid procedural volumes in the U.S.
 
The Company reported total net sales of $1.202 billion, a 5.5% increase as reported and an 8.5% increase on a constant currency basis, compared to $1.139 billion in the prior year. Full-year 2022 net sales growth was driven by further adoption of the Pulse platform and new products within the C360 portfolio, as well as continued strong international growth.
 
“Looking back at 2022, I am proud of our team for delivering another year of above-market, net sales growth,” said Chris Barry, chief executive officer of NuVasive. “Looking ahead, I couldn’t be more excited to join forces with Globus Medical to create a leading, global musculoskeletal technology company. Our complementary commercial organizations and product portfolios make a strong financial profile and value creation opportunity for shareholders—while furthering our ability to increase customer reach and change more patient lives.”

Full-year 2023 Net Sales Guidance